Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Spanish drug services firm Esteve to invest $108 million in plant expansion
by Aayushi Pratap
July 11, 2024
| A version of this story appeared in
Volume 102, Issue 21
Credit: Esteve
The Girona facility is one of three plants Esteve operates in Spain.
The pharmaceutical chemical firm Esteve will spend $108 million to build an active pharmaceutical ingredient production unit at its site in Girona, Spain. The funds will be used to construct new buildings and install up to 150 m3 of new reactor volume. The unit, expected to open in the fourth quarter of 2026, will increase the company’s global production capacity by 15% and add 100 employees to its workforce of 370, Esteve says.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X